source
- Tarsus Pharma to spend $450M upfront acquiring Alkeus to expand its ophthalmology pipelineTarsus Pharmaceuticals announced it will acquire Alkeus Pharmaceuticals, a Phase 3 biotech focused on a Stargardt disease drug, for an upfront payment of $450 million. The deal is intended to broad…
- LifeMine Therapeutics secures $263 million in dual venture rounds to advance organ transplant aftercare drugLifeMine Therapeutics announced it has raised a total of $263 million through a $75 million Series D and an $188 million Series F round, opting for private financing rather than an IPO. The capita…